Vincent Lewis, PA
Medical · Salisbury, MDNPI 1275791147
Payments from drug & device makers
Across 458 payments — averaging $16.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$967
- Pfizer$593
- AbbVie$535
- AstraZeneca$533
- GSK$485
- Novartis$472
- plus $4K from 29 others
What the payments were for
- Food & beverage$7,64698%
- Education$1312%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 54 | $967 |
| Pfizer | 41 | $593 |
| AbbVie | 33 | $535 |
| AstraZeneca | 26 | $533 |
| GSK | 33 | $485 |
| Novartis | 24 | $472 |
| Novo Nordisk | 29 | $470 |
| Amgen | 27 | $460 |
| Boehringer Ingelheim | 26 | $381 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $234 |
| Exact Sciences | 10 | $228 |
| Johnson & Johnson | 14 | $218 |
| Axsome Therapeutics, Inc. | 9 | $188 |
| Kowa Pharmaceuticals America, Inc. | 9 | $167 |
| Merck | 10 | $165 |
| Dexcom, Inc. | 7 | $156 |
| Esperion Therapeutics, Inc. | 10 | $148 |
| Phathom Pharmaceuticals, Inc. | 11 | $145 |
| Astellas Pharma US Inc | 4 | $139 |
| Bayer | 7 | $130 |
| Mylan Specialty L.p. | 7 | $125 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $124 |
| Sanofi-aventis U.S. LLC | 7 | $123 |
| Biohaven Pharmaceuticals, Inc. | 14 | $118 |
| Idorsia Pharmaceuticals US Inc | 6 | $102 |
| Medtronic | 4 | $87 |
| Corcept Therapeutics | 3 | $67 |
| Viatris Specialty LLC | 2 | $47 |
| Abbott | 2 | $37 |
| Amarin Pharma, Inc. | 2 | $35 |
| Sumitomo Pharma America, Inc. | 1 | $29 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $21 |
| Supernus Pharmaceuticals, Inc. | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Eisai Inc. | 1 | $15 |
How this compares
$7,777 in reported general payments places this provider in the 90th percentile of 543 medical providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 165 | $150,548 |
| OzempicSemaglutide | 78 | $86,008 |
| TrulicityDulaglutide | 64 | $85,509 |
| MounjaroTirzepatide | 65 | $74,207 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 98 | $72,465 |
| EliquisApixaban | 68 | $60,662 |
| JanuviaSitagliptin Phosphate | 54 | $55,985 |
| FarxigaDapagliflozin Propanediol | 60 | $55,621 |
| TradjentaLinagliptin | 33 | $37,738 |
| EntrestoSacubitril/Valsartan | 31 | $36,932 |
| LinzessLinaclotide | 38 | $33,444 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 24 | $33,199 |
| Repatha SureclickEvolocumab | 30 | $24,680 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 22 | $18,753 |
| VraylarCariprazine Hcl | 12 | $17,063 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $381 | $221,484222 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $967 | $159,716129 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Shingrix | $485 | $103,333181 claims |
| Novo NordiskOzempic | $470 | $86,00878 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $533 | $76,66293 claims |
| MerckJanuvia, Belsomra | $165 | $68,04982 claims |
| PfizerEliquis | $593 | $60,66268 claims |
| AbbVieLinzess, Vraylar | $535 | $50,50750 claims |
| NovartisEntresto | $472 | $36,93231 claims |
| Johnson & JohnsonXarelto | $218 | $15,65420 claims |
| Astellas Pharma US IncMyrbetriq | $139 | $8,12911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 543 medical providers in Maryland.
Other medical in Salisbury
- Brandon McMullenSalisbury$9K
- Victoria TrottStevensville$94K
- Sarah SagorskyBaltimore$68K
- Emily GrisnikLeonardtown$62K
- Jennifer HamiltonBel Air$52K
- Kristina TrunnellFrederick$51K
- Karen ScottAnnapolis$49K
- Nicholas WunderAberdeen$40K
- Sarah JamiesonFrederick$34K
- Jayme WilliamsCatonsville$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.